Effect of intravitreal aflibercept treatment on retinal vessel parameters in diabetic macular oedema: .

To evaluate the effects of intravitreal aflibercept (IVA) treatment on retinal vein parameters and choroidal thickness used in the treatment of diabetic macular oedema (DME). This retrospective study administered Afyonkarahisar Health Sciences University Department of Ophthalmology. Twenty-nine patients who were diagnosed with naive DME in a single eye were included in the study. A three consecutive, monthly intravitreal injection of 2 mg aflibercept were administered to patients. Each patient's contralateral (untreated) eyes, which did not diagnose DME and did not receive any treatment, were the control group. The central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-vein ratio (AVR) values were measured using a semi-automatically computer-based software before the first IVA injection and 30 d after the first, second, and third injections. The main outcome measurements were the central macular thickness (CMT), best-corrected visual acuity (BCVA), subfoveal choroidal thickness (sf-CT), CRAE, CRVE, and AVR. The mean age of patients was 59.25 ± 9.48 years. Patients were 15 males and 14 females. A significant vasoconstriction of the retinal arterioles, a thinning of sf-CT and CMT, and an increase of BCVA have observed in IVA-treated eyes compared to baseline (respectively,  < 0.001,  < 0.001,  < 0.001,  < 0.001). But, no significant differences were found for CRVE and AVR in IVA-treated eyes compared to baseline. No significant difference was found for all parameters in untreated eyes compared to baseline. This study demonstrates that IVA treatment can change retinal blood flow by reducing retinal artery diameter and thinning in the choroid.